Statins and the risk of colorectal cancer.
暂无分享,去创建一个
Ronit Almog | Stephen B Gruber | Gad Rennert | S. Gruber | G. Rennert | P. Higgins | J. Greenson | R. Almog | H. Rennert | J. Poynter | Joseph D Bonner | Peter D R Higgins | J. Bonner | M. Low | Jenny N Poynter | Hedy S Rennert | Marcelo Low | Joel K Greenson
[1] M. Minden,et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. , 1999, Blood.
[2] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[3] A. Gotto,et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. , 2001, The American journal of cardiology.
[4] G. Beck,et al. A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.
[5] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[6] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[7] J. Long,et al. Genetic anthropology of the colorectal cancer-susceptibility allele APC I1307K: evidence of genetic drift within the Ashkenazim. , 2003, American journal of human genetics.
[8] C. Rao,et al. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. , 2002, International journal of oncology.
[9] C. Rao,et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. , 1999, Gastroenterology.
[10] Barry R. Davis,et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.
[11] H. Buchwald. Cholesterol inhibition, cancer, and chemotherapy , 1992, The Lancet.
[12] F. Bernini,et al. Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin , 2004, Cardiovascular Drugs and Therapy.
[13] M. Sinensky,et al. Recent advances in the study of prenylated proteins. , 2000, Biochimica et biophysica acta.
[14] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[15] L. G. García Rodríguez,et al. Reduced Risk of Colorectal Cancer among Long-Term Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs , 2001, Epidemiology.
[16] Susan Halabi,et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.
[17] C. Elson,et al. Sterol‐independent regulation of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase in tumor cells , 2001, Molecular carcinogenesis.
[18] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[19] H Jick,et al. Statin use and cancer risk in the General Practice Research Database , 2004, British Journal of Cancer.
[20] C. Rao,et al. Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. , 2002, Cancer detection and prevention.
[21] L. Blais,et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. , 2000, Archives of internal medicine.
[22] S. H. Brown,et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. , 1994, Archives of internal medicine.
[23] J. Willerson. Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. , 1996, Circulation.
[24] J. Goldstein,et al. Regulation of the mevalonate pathway , 1990, Nature.
[25] B. Davis,et al. Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project , 2002, Circulation.
[26] P. Serruys,et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[27] M. Clearfield. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian simvastatin survival study. , 2005, Current atherosclerosis reports.
[28] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[29] Jennifer L. Kelsey,et al. Methods in Observational Epidemiology , 1986 .
[30] Henk-Jan Guchelaar,et al. The risk of cancer in users of statins. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Shapiro,et al. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma , 1998, Cancer.
[32] J E Frijters,et al. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. , 1982, The American journal of clinical nutrition.
[33] E. Shemesh,et al. Colorectal adenomatous polyps and carcinoma in ashkenazi and non‐ashkenazi jews in israel , 1986, Cancer.